Screener
ArriVent BioPharma, Inc. AVBP Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 54,724 | 6,516 |
| Proceeds from the exercise of stock options | 149 | 293 |
| Payment of deferred financing costs | — | (50) |
| Net cash provided by financing activities | 54,873 | 6,759 |
| Net increase (decrease) in cash and cash equivalents | 16,563 | (24,428) |
| Cash and cash equivalents at beginning of the year | 45,540 | 74,293 |
| Cash and cash equivalents at end of the year | $62,103 | $49,865 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s financing cash flow?
- ArriVent BioPharma, Inc. (AVBP) reported financing cash flow of $54.87M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s financing cash flow changed year-over-year?
- ArriVent BioPharma, Inc.'s financing cash flow increased by 711.9% year-over-year, from $6.76M to $54.87M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about ArriVent BioPharma, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude